Recruiting

DRISTi

Sponsor:

Artelus AI

Code:

NCT07222293

Conditions

Diabetic Retinopathy (DR)

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Accepted

Interventions

Fundus Image Grading

Study Details

Brief summary:

A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in the outcomes thus proving DRISTi is an effective DR diagnosis tool.

Conditions

Diabetic Retinopathy (DR)

Study ID

NCT07222293

Start date

Nov 23, 2025

Status verified date

Dec, 2025

Completion date

Mar, 2026

Anticipated

Primary completion date

Mar, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Ability to sign and date the informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Age (≥)21 years of age or older
4. Diagnosed with diabetes mellitus as per criteria established by the World Health Organization (WHO) or the American Diabetes Association (ADA)

1. Hemoglobin A1c (HbA1c) ≥ 6.5%
2. Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L)
3. Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)

Exclusion Criteria:

1. Persistent visual impairment in one or both eyes;
2. History of macular edema or retinal vascular (vein or artery) occlusion;
3. History of ocular injections, laser treatment of the retina, or intraocular surgery other than cataract surgery without complications;
4. Subject is contraindicated for fundus photography (for example, has light sensitivity);
5. Subject has contraindications for mydriatic medications or is unwilling or unable to dilate;
6. Subject is currently enrolled in an interventional study of an investigational device or drug for the same condition; or
7. Subject has a condition or is in a situation which in the opinion of the Investigator, might confound study results, may interfere significantly with the subject's participation in the study, or may result in ungradable clinical reference standard photographs
8. Subject falls into one of the below categories:

  • Adults unable to consent (individuals w/ impaired decision-making capacity)
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners

Study Design

Enrollment

900 participants

Anticipated

Interventions and Outcome Measures

Interventions

Fundus Image Grading

The image is graded by a fully automated AI device

Primary outcome measure

  • Accuracy of AI Grade [ Time Frame: From time of arrival to completion of diagnostic tests, up to 8 hours ]

Central Contacts and Locations

Central contacts

Jeanne Champion, Primary Site Coordinator Oxford

9192347003Jeanne@ncophth.com

Adriana Valencia, Site Coordinator Raleigh

9192347406Adriana@ncophth.com

Locations

New Century Ophthalmology - Oxford

Recruiting

Oxford, North Carolina, United States, 27565

Contacts

Jeanne Champion, Site Coordinator Oxford

9192347003Jeanne@ncophth.com

Chaitan Walia, Study Coordinator, BA

3129738490cpwalia7@gmail.com

Principal Investigator:

Vinod Jindal, MD

New Century Ophthalmology - Raleigh

Recruiting

Raleigh, North Carolina, United States, 27617

Contacts

Adriana Valencia, Site Coordinator Raleigh

9192347406Adriana@ncophth.com

Chaitan Walia, Study Coordinator, BA

3129738490cpwalia7@gmail.com

Principal Investigator:

Vinod Jindal, MD

More Information

Sponsor

Artelus AI

Last update posted

Dec 9, 2025

Last verified

Dec, 2025

Keywords

  • Artificial Intelligence
  • Ophthalmic Device
  • AI
  • Diabetic Retinopathy
  • Diabetes
  • DR
  • Screening
  • Online/Offline
  • Fundus Camera

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Artelus AI on 2025-12-09.